NYSE:BLCO Bausch + Lomb (BLCO) Stock Forecast, Price & News $16.95 +0.15 (+0.89%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$16.80▼$17.1450-Day Range$16.80▼$19.9052-Week Range$12.79▼$21.95Volume548,747 shsAverage Volume408,324 shsMarket Capitalization$5.94 billionP/E RatioN/ADividend YieldN/APrice Target$20.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bausch + Lomb MarketRank™ ForecastAnalyst RatingHold2.38 Rating ScoreUpside/Downside20.9% Upside$20.50 Price TargetShort InterestHealthy11.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth54.29%From $0.70 to $1.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector429th out of 969 stocksOphthalmic Goods Industry5th out of 7 stocks 3.2 Analyst's Opinion Consensus RatingBausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, Bausch + Lomb has a forecasted upside of 20.9% from its current price of $16.96.Amount of Analyst CoverageBausch + Lomb has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.21% of the float of Bausch + Lomb has been sold short.Short Interest Ratio / Days to CoverBausch + Lomb has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Bausch + Lomb has recently decreased by 14.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch + Lomb does not currently pay a dividend.Dividend GrowthBausch + Lomb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLCO. Previous Next 2.2 News and Social Media Coverage News SentimentBausch + Lomb has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bausch + Lomb this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch + Lomb insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 12.45% of the stock of Bausch + Lomb is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Bausch + Lomb are expected to grow by 54.29% in the coming year, from $0.70 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch + Lomb is -42.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch + Lomb is -42.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch + Lomb has a PEG Ratio of 3.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBausch + Lomb has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bausch + Lomb (NYSE:BLCO) StockBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Read More BLCO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLCO Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comFinancial Comparison: Signature Eyewear (OTCMKTS:SEYE) vs. Bausch + Lomb (NYSE:BLCO)September 26, 2023 | finance.yahoo.comBausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United StatesSeptember 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 21, 2023 | msn.comBausch Health stock rebounds from Tuesday sell-off, helped by Jefferies upgradeSeptember 20, 2023 | cnbc.comBuy this pharma stock that could more than double if it clears a legal battle, Jefferies saysSeptember 19, 2023 | finance.yahoo.comIs the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?September 14, 2023 | finance.yahoo.comBausch + Lomb Announces Pricing of Senior Secured Notes OfferingSeptember 12, 2023 | markets.businessinsider.comBausch + Lomb Launches MIEBO To Treat Dry Eye DiseaseSeptember 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 12, 2023 | finance.yahoo.comBausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United StatesSeptember 11, 2023 | finanznachrichten.deBausch Health Companies Inc.: Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRASeptember 11, 2023 | markets.businessinsider.comBausch + Lomb Unit Launches Offering Of $1.4 Bln Of New Senior Secured NotesSeptember 11, 2023 | finance.yahoo.comBausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®September 11, 2023 | finance.yahoo.comBausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)September 6, 2023 | businesswire.comBausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRASeptember 6, 2023 | finance.yahoo.comBausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®September 6, 2023 | finance.yahoo.comBausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual MeetingSeptember 5, 2023 | nasdaq.comBausch + Lomb (XTSE:BLCO) Price Target Increased by 5.96% to 29.94August 29, 2023 | finance.yahoo.comBausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare ConferenceAugust 24, 2023 | businesswire.comBausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRAAugust 24, 2023 | finance.yahoo.comBausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®August 23, 2023 | fool.comBausch + Lomb (NYSE: BLCO)August 9, 2023 | seekingalpha.comBausch + Lomb: Growth Should Accelerate As Supply Issues EaseAugust 3, 2023 | cnbc.comTroubled health name bounces after strong quarter and guidance. Here's our view on the stockAugust 3, 2023 | msn.comMorgan Stanley Reiterates Bausch + Lomb (BLCO) Equal-Weight RecommendationAugust 3, 2023 | markets.businessinsider.comBarclays Sticks to Its Hold Rating for Bausch + Lomb Corporation (BLCO)August 2, 2023 | finance.yahoo.comBausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue OutlookSee More Headlines Receive BLCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCO Company Calendar Last Earnings8/02/2023Today9/30/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNYSE:BLCO CUSIPN/A CIK1860742 Webwww.bausch.com Phone905-695-7700FaxN/AEmployees12,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+20.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E Ratio24.23 P/E Growth3.92Net Income$6 million Net Margins-3.61% Pretax Margin-1.46% Return on Equity4.09% Return on Assets2.58% Debt Debt-to-Equity Ratio0.37 Current Ratio1.75 Quick Ratio1.22 Sales & Book Value Annual Sales$3.77 billion Price / Sales1.58 Cash Flow$2.20 per share Price / Cash Flow7.72 Book Value$20.29 per share Price / Book0.84Miscellaneous Outstanding Shares350,710,000Free FloatN/AMarket Cap$5.95 billion OptionableNot Optionable Beta0.22 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Osama A. Eldessouky (Age 51)Exec. VP & CFO Comp: $1.09MDr. Yehia Hashad M.D. (Age 56)Exec. VP of R&D and Chief Medical officer Comp: $1.09MMr. Brenton L. Saunders J.D. (Age 53)CEO & Chairman Mr. Alan Waterhouse CPFA (Age 63)MBA, Exec. VP and Chief Supply Chain & Operations Officer Mr. Frederick J. Munsch (Age 53)Sr. VP, Controller & Chief Accounting Officer Mr. A. Robert D. Bailey (Age 60)Exec. VP & Chief Legal Officer Mr. Jonathon L. KellermanChief Compliance OfficerT.J. CrawfordChief Communications OfficerDr. Manisha A. Narasimhan Ph.D. (Age 46)Chief Corp. Devel. & Digital Officer Ms. Asli GevgililiExec. VP & Chief HR OfficerMore ExecutivesKey CompetitorsSTAAR SurgicalNASDAQ:STAACooper CompaniesNYSE:COOOption Care HealthNASDAQ:OPCHGrifolsNASDAQ:GRFSAcadia HealthcareNASDAQ:ACHCView All CompetitorsInstitutional OwnershipAlamar Capital Management LLCBought 2,159 shares on 8/24/2023Ownership: 0.031%Clearline Capital LPSold 1,800 shares on 8/15/2023Ownership: 0.071%Citadel Advisors LLCBought 1,100 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 12,586 shares on 8/15/2023Ownership: 0.005%Walleye Trading LLCBought 13,900 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions BLCO Stock - Frequently Asked Questions Should I buy or sell Bausch + Lomb stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares. View BLCO analyst ratings or view top-rated stocks. What is Bausch + Lomb's stock price forecast for 2023? 8 brokerages have issued 12 month price objectives for Bausch + Lomb's shares. Their BLCO share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts. How have BLCO shares performed in 2023? Bausch + Lomb's stock was trading at $15.51 at the start of the year. Since then, BLCO stock has increased by 9.3% and is now trading at $16.96. View the best growth stocks for 2023 here. Are investors shorting Bausch + Lomb? Bausch + Lomb saw a drop in short interest in September. As of September 15th, there was short interest totaling 4,270,000 shares, a drop of 14.3% from the August 31st total of 4,980,000 shares. Based on an average daily volume of 482,700 shares, the short-interest ratio is presently 8.8 days. Currently, 11.2% of the shares of the company are sold short. View Bausch + Lomb's Short Interest. When is Bausch + Lomb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our BLCO earnings forecast. How were Bausch + Lomb's earnings last quarter? Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.02. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $963.69 million. Bausch + Lomb had a positive trailing twelve-month return on equity of 4.09% and a negative net margin of 3.61%. Bausch + Lomb's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business earned $0.29 EPS. What ETFs hold Bausch + Lomb's stock? ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX). What guidance has Bausch + Lomb issued on next quarter's earnings? Bausch + Lomb updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.95 billion-$4.00 billion, compared to the consensus revenue estimate of $5.20 billion. When did Bausch + Lomb IPO? (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share. What is Bausch + Lomb's stock symbol? Bausch + Lomb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLCO." How do I buy shares of Bausch + Lomb? Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bausch + Lomb's stock price today? One share of BLCO stock can currently be purchased for approximately $16.96. How much money does Bausch + Lomb make? Bausch + Lomb (NYSE:BLCO) has a market capitalization of $5.95 billion and generates $3.77 billion in revenue each year. The company earns $6 million in net income (profit) each year or ($0.40) on an earnings per share basis. How many employees does Bausch + Lomb have? The company employs 12,900 workers across the globe. How can I contact Bausch + Lomb? The official website for the company is www.bausch.com. The company can be reached via phone at 905-695-7700. This page (NYSE:BLCO) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.